Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology: Neuroimmunology & Neuroinflammation COVID-19 Article Hub
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
    • UDDA Revision Series
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology: Neuroimmunology & Neuroinflammation COVID-19 Article Hub
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
    • UDDA Revision Series
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit Manuscript
    • Author Center
  • Home
  • Articles
  • Issues
  • COVID-19 Article Hub
  • Infographics & Video Summaries

User menu

  • My Alerts
  • Log in
  • Log out

Search

  • Advanced search
Neurology Neuroimmunology & Neuroinflammation
Home
A peer-reviewed clinical and translational neurology open access journal
  • My Alerts
  • Log in
  • Log out
Site Logo
  • Home
  • Articles
  • Issues
  • COVID-19 Article Hub
  • Infographics & Video Summaries

Share

September 2020; 7 (5) Clinical/Scientific NotesOpen Access

COVID-19-associated acute necrotizing myelitis

Javier Sotoca, Yensa Rodríguez-Álvarez
First published June 10, 2020, DOI: https://doi.org/10.1212/NXI.0000000000000803
Javier Sotoca
From the Neurology Department (J.S.) and Radiology Department (Y.R.-Á.), Hospital Universitari Mútua Terrassa, Spain.
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yensa Rodríguez-Álvarez
From the Neurology Department (J.S.) and Radiology Department (Y.R.-Á.), Hospital Universitari Mútua Terrassa, Spain.
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
COVID-19-associated acute necrotizing myelitis
Javier Sotoca, Yensa Rodríguez-Álvarez
Neurol Neuroimmunol Neuroinflamm Sep 2020, 7 (5) e803; DOI: 10.1212/NXI.0000000000000803

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
1436

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

A 69-year-old otherwise healthy woman presented to our clinic with irradiated cervical pain, imbalance, and motor weakness and numbness in the left hand, which had been ongoing for 7 days. Eight days before the onset of these symptoms, she had fever and dry cough.

On admission, her neurologic examination showed right facial and left hand hypoesthesia, subtle left hand interosseous weakness, and general hyperreflexia.

MRI of the brain was normal, whereas spinal cord images (figure 1, A and D) showed T2-hyperintensity extending from the medulla oblongata to C7, involving most of the cord with diffuse patchy enhancing lesions, suggesting acute transverse myelitis.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure Spinal MRI evolution of LETM with necrotizing area

Sagittal T2-weighted (A–C) and sagittal postcontrast T1-weighted (D–F). Baseline performed (A and D), follow-up 1 week (B and E), and plasmapheresis posttreatment (C and F). A LETM is seen in the cervical spinal cord (A) with patchy enhancement (D). Progressive swelling of the spinal cord and a new necrotizing area (B: arrow) that shows peripheral enhancement (E: arrow). Significant decreases of both myelitis extension (C) and enhancement (F) after plasmapheresis treatment, with necrosis area in evolution. LETM = longitudinal extensive transverse myelitis.

Extensive diagnostic workup was performed, showing negative results in blood test for infectious, autoimmune diseases (including myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies), and other potential causes such as vitamin deficits or antiphospholipid syndrome.

The patient's CSF analysis showed a traumatic puncture (75 erythrocytes/μL), mild lymphocytic pleocytosis (75 cells/μL, 98% lymphocytes), hyperproteinorraquia of 2.83 g/L, normal adenosine deaminase, and glucose results; IgG index was normal, no oligoclonal bands were present, and bacterial culture and viral multi-PCR test were also negative. The presence of neuronal surface antibodies was also ruled out. Thoracoabdominal CT scan was negative for tumor and lymphadenopathy. SARS-CoV-2 PCR was positive in nasopharyngeal swab and negative in CSF. No cytokine levels were examined neither in serum nor CSF.

Treatment with methylprednisolone 1 g IV for 5 days resulted in initial improvement. However, a few days later, her clinical condition worsened markedly: she developed sensory motor deficits in both hands and paraparesis with sphincter incontinence.

A new spinal MRI was performed (figure 1, B and E), showing transversally and caudally progression until T6 level with similar enhancement and a new area of central necrosis at the T1 level with peripheral enhancement.

Treatment with plasma exchange and other course of methylprednisolone pulses for 5 days with posterior slow oral prednisone tapering resulted in improvement of strength and motor function, until being able to walk with assistance, use electronic devices such as typing on her mobile phone or write with some difficulties, remaining left leg moderate weakness and no sphincter control. After 4 weeks from the clinical onset, she continues improving slowly and performing physical and occupational therapy.

Spinal MRI postplasmapheresis (figure 1, C and F) showed substantial decrease in myelitis extension and enhancement, but central necrosis at the C7-T1 level remained unchanged.

Acute necrotizing myelitis (ANM) is a rare inflammatory disorder of the spinal cord. Only a few cases have been associated to inflammatory diseases such as neuromyelitis optica or vasculitis, paraneoplastic mechanisms, or adverse effect of new oncologic treatments.1,–,3

Spine MRI in ANM usually shows hypointense T1 signal and corresponding increase in T2 signal and, characteristically, hemorrhage, cavitation, and postcontrast enhancement could also be seen.

The exact pathogenesis of ANM remains obscure, and analogously to acute necrotizing encephalitis (ANE), an inflammatory response (“cytokine storm”) secondary to a viral infection has been postulated as a possible cause.4 Human coronaviruses are a group of respiratory viruses that can naturally reach the CNS in humans through hematogenous or neuronal retrograde route and could potentially be associated with neurologic symptoms.5 A systemic cytokine production due to the SARS-CoV-2 infection has been suggested to contribute to the pathophysiology of severe coronavirus disease 2019 (COVID-19).6 Recently, a case of ANE caused by the new coronavirus infection has been reported.7

In our patient, the presence of a longitudinal extensive transverse myelitis with subsequent worsening along with development of a necrotic area, associated with focal swelling, peripheral enhancement, and hypointense foci on T2 images, led us to the diagnosis of ANM in a patient COVID-19 positive. Immunomodulatory treatment such as steroids or plasmapheresis can result in neurologic improvement as the patient reported here.

Additional studies are needed to better define the potential role of human coronaviruses in the pathogenesis and the effectiveness of any therapeutic measure in the management of ANM.

Study funding

Not related to this manuscript..

Disclosure

J. Sotoca reports no disclosures relevant to the manuscript. Y. Rodríguez-Álvarez reports no disclosures relevant to the manuscript. Go to Neurology.org/NN for full disclosures.

Acknowledgment

The authors thank the patient and all the physicians and health personnel involved in the care of patients in the COVID-19 pandemic.

Appendix Authors

Table

Footnotes

  • Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article.

  • The article processing charge was funded by the authors.

  • Received May 11, 2020.
  • Accepted in final form May 18, 2020.
  • Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

References

  1. 1.↵
    1. Katz JD,
    2. Ropper AH
    . Progressive necrotic myelopathy. Arch Neurol 2000;57:355.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Okai AF,
    2. Muppidi S,
    3. Bagla R,
    4. Leist TP
    . Progressive necrotizing myelopathy: Part of the spectrum of neuromyelitis optica? Neurol Res 2006;28:354–359.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Abdallah AO,
    2. Herlopian A,
    3. Ravilla R, et al
    . Ipilimumab-induced necrotic myelopathy in a patient with metastatic melanoma: a case report and review of literature. J Oncol Pharm Pract 2016;22:537–542.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Kansagra SM,
    2. Gallentine WB
    . Cytokine storm of acute necrotizing encephalopathy. Pediatr Neurol 2011;45:400–402.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Desforges M,
    2. Le Coupanec A,
    3. Dubeau P, et al
    . Human coronaviruses and other respiratory viruses: underestimated opportunistic pathogens of the central nervous system? Viruses 2019;12:1–28.
    OpenUrl
  6. 6.↵
    1. Moore JB,
    2. June CH
    . Cytokine release syndrome in severe COVID-19. Science 2020;368:473–474.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Poyadji N,
    2. Shahin G,
    3. Noujaim D, et al
    . COVID-19 associated acute hemorrhagic necrotizing encephalopathy: CT and MRI features. Radiology 2020:201187. doi: 10.1148/radiol.2020201187.
    OpenUrlCrossRef

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Study funding
    • Disclosure
    • Acknowledgment
    • Appendix Authors
    • Footnotes
    • References
  • Figures & Data
  • Info & Disclosures
Advertisement

Association Between Fluctuations in Blood Lipid Levels Over Time With Incident Alzheimer Disease and Alzheimer Disease–Related Dementias

Dr. Sevil Yaşar and Dr. Behnam Sabayan

► Watch

Related Articles

  • No related articles found.

Topics Discussed

  • All Spinal Cord
  • All Demyelinating disease (CNS)
  • MRI
  • COVID-19
  • Transverse myelitis

Alert Me

  • Alert me when eletters are published

Recommended articles

  • Views & Reviews
    Presentations and mechanisms of CNS disorders related to COVID-19
    Marta Bodro, Yaroslau Compta, Raquel Sánchez-Valle et al.
    Neurology: Neuroimmunology & Neuroinflammation, December 11, 2020
  • Review
    Potential Neurologic Manifestations of COVID-19
    Anna S. Nordvig, Kathryn T. Fong, Joshua Z. Willey et al.
    Neurology: Clinical Practice, June 30, 2020
  • Article
    Encephalopathies Associated With Severe COVID-19 Present Neurovascular Unit Alterations Without Evidence for Strong Neuroinflammation
    Raphael Bernard-Valnet, Sylvain Perriot, Mathieu Canales et al.
    Neurology: Neuroimmunology & Neuroinflammation, June 16, 2021
  • Article
    COVID-19 in Patients With Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody Disease in North America
    From the COViMS Registry
    Scott D. Newsome, Anne H. Cross, Robert J. Fox et al.
    Neurology: Neuroimmunology & Neuroinflammation, August 24, 2021
Neurology - Neuroimmunology Neuroinflammation: 10 (6)

Articles

  • Articles
  • Issues
  • Popular Articles

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology: Neuroimmunology & Neuroinflammation
Online ISSN: 2332-7812

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise